2026 Houston Patient and Family Conference
CONFERENCE AGENDA - November 7, 2026
8:00 - 2:45 (Central Time Zone)
Acute Myeloid Leukemia (AML)
2026 Columbus Patient and Family Conference
Saturday, October 24, 2026
Conference Co-Chairs
Uma Borate, MBBS
Alice Mims, MD
Xiaoyi Chen, MD, PhD
Institution
Rutgers Cancer Institute of New Jersey
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Chen is currently with the Rutgers Cancer Institute, the only NCI-designated cancer center in the state, where cutting-edge cancer research is conducted and state-of-the-art cancer care is delivered. Her interest in hematological malignancies started in medical school, driving her to pursue research in this field. After graduating from West China Medical School, she joined the University of Cincinnati’s Cancer and Cell Biology program, where her primary research focused on targeting autophagy in acute leukemia and earned my PhD. Following this, she completed her internal medicine residency
Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study
Original Publication Date
Article Source
External Web Content
Abstract Introduction Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result…
Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study
Original Publication Date
Article Source
External Web Content
Summary Reduced-intensity conditioning (RIC) is associated with a high relapse rate in high-risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). It remains unclear whether venetoclax, an…
When the Backbone Becomes the Platform: Rethinking Induction in Acute Myeloid Leukemia
Original Publication Date
Article Source
External Web Content
For most of the last 50 years, the conversation with a patient with newly diagnosed acute myeloid leukemia (AML) who is fit for intensive chemotherapy (IC) has followed a familiar script. The goal of therapy is cure, but to achieve this goal, we have to give IC, with the caveat…
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
Original Publication Date
Article Source
External Web Content
In a single-center phase I to II trial (SAVE) reported in the Journal of Clinical Oncology, Issa et al found that the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax was highly active in patients with relapsed or refractory acute myeloid leukemia (AML)…
Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21
Original Publication Date
Article Source
External Web Content
TO THE EDITOR: In older patients with acute myeloid leukemia (AML), cure by hematopoietic stem cell transplantation (HSCT) is often not achieved after standard intensive chemotherapy (IC) because of intercurrent infections or other sequelae of IC. Extended, that is, 10-day…
Leukemic Transformation From the 2026 AAMDSIF Seattle Patient and Family Conference
Topic(s)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Anna Halpern, MD
Dr. Anna Halpern discusses how leukemic transformation is identified, what it means for prognosis, and how patients and their healthcare teams can navigate treatment decisions.